Shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) traded up 4.3% during trading on Tuesday . The stock traded as high as $49.96 and last traded at $49.62, with a volume of 554,081 shares changing hands. The stock had previously closed at $47.57.

AGIO has been the topic of a number of research analyst reports. Canaccord Genuity upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the stock from $50.00 to $90.00 in a report on Monday, June 13th. Vetr upgraded Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.42 price target on the stock in a report on Monday, June 13th. BTIG Research initiated coverage on Agios Pharmaceuticals in a report on Friday, August 19th. They set a “neutral” rating on the stock. JPMorgan Chase & Co. upgraded Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $50.00 to $62.00 in a report on Monday, June 13th. Finally, Goldman Sachs Group Inc. restated a “neutral” rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a report on Wednesday, August 10th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $63.44.

The company’s market capitalization is $1.99 billion. The company’s 50 day moving average price is $42.03 and its 200-day moving average price is $45.12.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.99. The company earned $6.98 million during the quarter, compared to analysts’ expectations of $39.62 million. Agios Pharmaceuticals had a negative return on equity of 47.69% and a negative net margin of 320.33%. Agios Pharmaceuticals’s revenue for the quarter was down 47.2% on a year-over-year basis. During the same period last year, the firm earned ($0.85) earnings per share. On average, equities research analysts anticipate that Agios Pharmaceuticals Inc. will post ($5.04) earnings per share for the current fiscal year.

In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 627 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $40.37, for a total value of $25,311.99. Following the transaction, the director now directly owns 125,921 shares of the company’s stock, valued at approximately $5,083,430.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.55% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of the stock. Public Employees Retirement Association of Colorado boosted its position in Agios Pharmaceuticals by 1.4% in the second quarter. Public Employees Retirement Association of Colorado now owns 6,110 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 82 shares during the period. Paradigm Asset Management Co. LLC boosted its position in Agios Pharmaceuticals by 3.4% in the second quarter. Paradigm Asset Management Co. LLC now owns 9,100 shares of the biopharmaceutical company’s stock valued at $381,000 after buying an additional 300 shares during the period. ProShare Advisors LLC boosted its position in Agios Pharmaceuticals by 1.8% in the second quarter. ProShare Advisors LLC now owns 29,110 shares of the biopharmaceutical company’s stock valued at $1,220,000 after buying an additional 525 shares during the period. State of Wisconsin Investment Board boosted its position in Agios Pharmaceuticals by 3.4% in the second quarter. State of Wisconsin Investment Board now owns 18,470 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 600 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in Agios Pharmaceuticals by 32.6% in the first quarter. Envestnet Asset Management Inc. now owns 2,769 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 680 shares during the period. 93.20% of the stock is currently owned by hedge funds and other institutional investors.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.